Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Edema, Pain, and Respiratory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TRPV4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Complex Membrane) | TRPV4 Lentivirus Premade Particles For stable cell line generation. Sequence Verified. |
View TRPV4 Products |
| Gene Delivery | TRPV4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View TRPV4 Products |
| Benchmark Ab | Anti-TRPV4 Recombinant Antibody Recombinant positive control. |
View TRPV4 Products |
| Validator | TRPV4 siRNA Set For knockdown verification. |
View TRPV4 Products |
| Related Target A | TRPV1 Synergistic pain pathway channel |
View TRPV1 Products |
| Related Target B | TRPA1 Sensory neuron co-expression channel |
View TRPA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Multi-pass Membrane Protein Conformation | Lentivirus-mediated stable cell lines ensuring native expression for Calcium Flux |
| Subfamily counter screening (TRPV1-6) | Comprehensive TRP channel panel lentivirus for selectivity profiling |
| Lack of Controls | Clinical Benchmark Antibodies included |
| False Positives | Validated siRNA included for specificity checks |
Live TRPV4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TRPV4 therapeutics is intensifying, with major players focusing on small molecule antagonists to treat pulmonary edema, heart failure, and chronic pain. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective, well-tolerated modulators that avoid off-target effects on bone homeostasis and other TRP channels.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | GSK, Novartis | Pulmonary Edema, Heart Failure | Selectivity Assay (Need Lentivirus for Cell-based Calcium Flux) |
| Small Molecule Agonists | Academic/Biotech | Endothelial Dysfunction | Functional Activation (Native Conformation required) |
| siRNA/Antisense | Preclinical | Neuropathic Pain | Knockdown Validation (Need positive control antibodies) |